CheckMate-451: Bristol-Myers’ Opdivo — plus Yervoy — fails PhIII combo lung cancer study, the latest in a series of setbacks
Bristol-Myers Squibb $BMY is becoming well practiced at disappointing investors with their R&D strategy for lung cancer.
After the market closed Monday the pharma giant reported that their Phase III trial matching Opdivo and their CTLA-4 drug Yervoy for CheckMate-451 failed on the primary endpoint for overall survival. Researchers were studying the combination as a maintenance therapy for small cell lung cancer after a first round of chemo, and this was one of the late-stage studies that analysts have been waiting for.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.